ADICET-ADI-001-BCELL
Phase I
OPEN TO ACCRUAL
A Phase 1 Safety and Efficacy Study of ADI-001 Anti-CD20 CAR-Engineered Allogeneic Gamma-Delta T Cells in Adults with Refractory B-Cell Malignancies
ALLOGENE-ALLO-501A-201
Phase I
OPEN TO ACCRUAL
A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-501A, an Anti-CD19 Allogeneic CAR T Cell Therapy, and ALLO-647, an Anti-CD52 Monoclonal Antibody, in Subjects with Relapsed/Refractory Large B-Cell Lymphoma (LBCL)
BEIGENE-BGB-11417-105
Phase I/II
OPEN TO ACCRUAL
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417 as Monotherapy, in Combination with Dexamethasone and Carfilzomib/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and t(11;14)
CELGENE-CC-92328-MM-001
Phase I
OPEN TO ACCRUAL
A Phase 1, Multi-Center, Open-Label, Dose Finding Study of CC-92328 in Subjects with Relapsed and/or Refractory Multiple Myeloma
CHIMAGEN-CMG1A46-US01
Phase I/II
OPEN TO ACCRUAL
A Phase 1/2, First in Human, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of Triple-Specific T-Cell Engager 1A46 in Adult Patients with Advanced CD20 and/or CD19 Positive B-Cell Hematologic Malignancies
DISC-0974-102
Phase I/II
OPEN TO ACCRUAL
A Phase 1b/2a Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DISC-0974 in Participants with Myelofibrosis and Anemia
GENMAB-GCT3014-01
Phase I/II
OPEN TO ACCRUAL
An Open-Label, Multicenter, Phase 1/2 Trial of GEN3014 (HexaBody-CD38) in Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies
IIT-ATALLAH-MCW-XEN21
Phase I
OPEN TO ACCRUAL
MCW-XEN21: A Phase 1 Study of XmAb18968 (CD3-CD38) for the Treatment of Patients with Relapsed/Refractory CD38 Positive Acute Leukemia and T Cell Lymphoblastic Lymphoma
IIT-SHAH-IL7-IL15-CD20-19
Phase I/II
OPEN TO ACCRUAL
Phase I/II Study of Tandem, Bispecific Anti-CD19 Anti-CD20 CAR-T Cells for Patients with Relapsed and/or Refractory B Cell Malignancies
JNJ-75276617ALE1001
Phase I
OPEN TO ACCRUAL
A First in Human Study of the Menin-KMT2A (MLL1) Inhibitor JNJ-75276617 in Participants with Acute Leukemia
JUNO-017004-TRANSCEND-CLL
Phase I/II
OPEN TO ACCRUAL
An Open-Label, Phase 1/2 Study of JCAR017 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004)
KRONOS-KB-LANRA-1001
Phase I/II
OPEN TO ACCRUAL
A Phase 1b/2 Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of the Selective SYK Inhibitor Lanraplenib (LANRA) in Combination with the FLT3 Inhibitor Gilteritinib, in Patients with FLT3-Mutated Relapsed or Refractory AML
MEI-ME-522-001
Phase I
OPEN TO ACCRUAL
A Phase 1, Open-label, Study of Voruciclib in Subjects with Relapsed and/or Refractory B-cell Malignancies or Acute Myeloid Leukemia after Failure of Prior Standard Therapies and Voruciclib in Combination with Venetoclax in Subjects with Relapsed and/or Refractory Acute Myeloid Leukemia
TAKEDA-TAK-981-1503
Phase I/II
OPEN TO ACCRUAL
A Phase 1b/2 Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of TAK-981 in Combination with Monoclonal Antibodies in Adult Patients with Relapsed and/or Refractory Multiple Myeloma
TENEOBIO-TENEOTWO-TNB486-001
Phase I
OPEN TO ACCRUAL
A Multicenter, Phase 1, Open-Label, Dose-Escalation and Expansion Study of TNB-486, a Bispecific Antibody Targeting CD19 in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
XENCOR-XMAB13676-01
Phase I
OPEN TO ACCRUAL
A Phase 1 Multidose Study to Evaluate the Safety and Tolerability of XmAb13676 (Plamotamab) in Patients with CD20-Expressing Hematologic Malignancies